EN
ENVB.US Enveric Biosciences Inc
- Market cap
- USD 6.78M
- P/E
- -
- P/B
- 0.84x
- ROE
- -167.9%
- Dividend yield
- 49.54%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ENVB.US undervalued?
Graham numberThe Graham number of Enveric Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enveric Biosciences Inc fundamental analysis
No fundamental analysis for Enveric Biosciences Inc yet.
Enveric Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to targe…
Full company profileEnveric Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Enveric Biosciences Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 36.1M | 48.6M | 43.0M | 39.9M | 39.9M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 6.54M | 10.2M | 8.98M | 8.15M | -121K | -682K | -435K | -408K | -337K | -201K | - |
| Operating Income | -5.38M | -12.0M | -7.15M | -6.32M | -5.62M | -25.9M | -20.0M | -16.4M | -9.63M | -8.77M | -9.63M |
| EBITDA | -4.41M | -7.67M | -6.92M | -2.26M | -6.30M | -55.7M | -19.5M | -16.9M | -9.23M | -8.57M | -9.49M |
| Net Income | -2.78M | -9.07M | -16.9M | -5.60M | -6.86M | -49.0M | -18.5M | -17.3K | -9.57M | -12.1M | -9.61M |
| EPS | -12,755 | -36,299 | -42,670 | -9,547 | -10,743 | -18,665 | -2,304 | -1.44 | -228 | -36 | -2.14 |
| Balance Sheet | |||||||||||
| Total Assets | 39.5M | 52.2M | 29.6M | 25.0M | 4.10M | 26.7M | 19.6M | 4.30M | 3.08M | 5.10M | 6.37M |
| Total Liabilities | 27.8M | 32.7M | 18.9M | 14.4M | 681K | 4.41M | 4.00M | 2.34M | 1.49M | 918K | 644K |
| Shareholders' Equity | 11.7M | 19.4M | 10.8M | 10.6M | 3.42M | 22.3M | 15.6M | 1.96M | 1.59M | 4.18M | 5.73M |
| Cash & Short-term Investments | 1.46M | 4.88M | 1.37M | 431K | 1.58M | 17.4M | 17.7M | 2.29M | 2.24M | 4.68M | 5.61M |
| Total Debt | 5.03M | 7.18M | 5.21M | 4.88M | 4.88M | 176K | 63.8K | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.70M | -2.74M | -2.57M | -648K | -3.89M | -11.5M | -17.1M | -14.1M | -7.73M | -8.14M | -9.80M |
| Capital Expenditure | 3.69M | 4.84K | 190K | 84.3K | 44.1K | 865K | 584K | 5.18K | 0.00 | 3.00 | 0.00 |
| Free Cash Flow | -6.39M | -2.75M | -2.57M | -648K | -3.93M | -12.3M | -17.7M | -14.1M | -7.73M | -8.14M | -9.80M |
| Ratios | |||||||||||
| ROE | -23.8% | -46.7% | -157.1% | -52.8% | -201.0% | -219.6% | -118.9% | -0.9% | -601.1% | -290.4% | -167.9% |
| ROA | -7.0% | -17.4% | -57.0% | -22.4% | -167.6% | -183.3% | -94.6% | -0.4% | -310.6% | -238.1% | -150.9% |
| Net Profit Margin | -7.7% | -18.7% | -39.3% | -14.0% | -17.2% | - | - | - | - | - | - |
| Debt to Equity | 0.43x | 0.37x | 0.48x | 0.46x | 1.43x | 0.01x | 0.00x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Enveric Biosciences Inc dividends
- Dividend yield
- 49.54%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Apr 23, 2008
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 3.36M | 10 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 2.09T | 5,275,633,838 | - |
| 2017 | USD 2.09B | 8,356,604 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:12 on Oct 28, 2025.
Who owns Enveric Biosciences Inc
- Insiders 8.89%
- Institutions 15.79%
- Public & others 75.32%
- Shares outstanding 4.48M
- Free float 4.01M
Top funds holding ENVB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 17.6K | 0.39% | 0.00% | Sep 2026 |
Top institutions holding ENVB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sio Capital Management, LLC | 180K | 4.02% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 100K | 2.23% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 35.4K | 0.79% | +108.65% | Jun 2026 |
| Renaissance Technologies Corp | 32.1K | 0.72% | 0.00% | Jun 2026 |
| Armistice Capital, LLC | 32.0K | 0.71% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 30.1K | 0.67% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 19.0K | 0.42% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 15.5K | 0.35% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 14.9K | 0.33% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 14.0K | 0.31% | 0.00% | Jun 2026 |
| StoneX Group Inc | 11.8K | 0.26% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 11.8K | 0.26% | -63.31% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 10.7K | 0.24% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 10.7K | 0.24% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 4.98K | 0.11% | +351.86% | Jun 2026 |
| SBI Securities Co Ltd | 2.68K | 0.06% | +3,124.10% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.00K | 0.02% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 702.00 | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 201.00 | 0.00% | -94.44% | Jun 2026 |
| BlackRock Inc | 51.00 | 0.00% | 0.00% | Jun 2026 |
Enveric Biosciences Inc company profile
- Company name
- Enveric Biosciences Inc
- Ticker
- ENVB.US
- Exchange
- USA Stocks
- Listed since
- Jun 24, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 245 First Street, Cambridge, MA, United States, 02142
- Phone
- 617 444 8400
- Website
- enveric.com
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Enveric Biosciences Inc management
3- Dr. Joseph Edward Tucker Ph.D.CEO & Director · born 1968
- Mr. Kevin M. Coveney CPAChief Financial Officer · born 1964
- Dr. Peter J. Facchini Ph.D.Chief Innovation Officer · born 1964